Semaglutide is a weekly injectable (or daily oral) GLP-1 receptor agonist approved for type 2 diabetes and obesity, with strong evidence for weight loss and cardiovascular risk reduction.
What it does
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It tells the pancreas to release insulin, tells the liver to stop dumping glucose, and tells your brain you're full. Native GLP-1 is destroyed within two minutes by an enzyme called DPP-IV. Semaglutide solves that problem with two structural tweaks: a fatty acid chain that anchors it to albumin (a blood protein) and a single amino acid swap that blocks DPP-IV from breaking it down. The result is a half-life of roughly seven days — one weekly injection sustains therapeutic levels all week Milena 2025.
On the metabolic side, semaglutide binds GLP-1 receptors on pancreatic beta-cells, triggering insulin release only when blood glucose is elevated. This glucose-dependent mechanism is why dangerous low blood sugar (hypoglycemia) is uncommon in people without diabetes. It also acts on pancreatic alpha-cells to suppress glucagon, the hormone that drives the liver to release stored glucose Brian 2025. Together these two effects smooth out post-meal glucose spikes.
The appetite piece is central to its weight-loss effect. GLP-1 receptors sit in several brain regions — the hypothalamus, the area postrema, and the nucleus tractus solitarius — that regulate hunger and satiety. Semaglutide crosses the blood-brain barrier and activates these receptors directly, reducing caloric intake by roughly 20–30% in clinical studies Anna 2026. It also slows gastric emptying (the rate food leaves the stomach), which extends the feeling of fullness after meals but is also the main driver of early nausea NCT06987669.
What the evidence shows
Weight loss in obesity Strong human trial evidence — multiple large RCTs
The STEP trials established 2.4 mg subcutaneous semaglutide (Wegovy) as the most effective approved pharmacotherapy for obesity to date. STEP 1 (N=1,961) showed ~15% mean body weight reduction over 68 weeks versus ~2.4% with placebo. The oral formulation (Rybelsus, 50 mg daily) was tested in the OASIS 1 trial and produced ~15% weight loss as well NCT05035095. Effects plateau without continued use — most weight returns after stopping Anna 2026.
Type 2 diabetes glycemic control Strong human trial evidence — regulatory-grade RCTs
Semaglutide lowers HbA1c (a 3-month average of blood glucose) by roughly 1.5–2.0 percentage points at standard doses, outperforming most oral agents in head-to-head trials. GLP-1 receptor agonists as a class, including semaglutide, also show meaningful reductions in progression from prediabetes to type 2 diabetes in high-risk patients I 2025. The glucose-dependent insulin release mechanism makes it usable across a wide range of baseline glucose levels without significant hypoglycemia risk Brian 2025.
Cardiovascular risk reduction Strong human evidence — large outcomes trial (N=17,604)
The SELECT trial enrolled over 17,000 people with obesity and established cardiovascular disease (but not diabetes) and found a 20% reduction in major adverse cardiovascular events (MACE — heart attack, stroke, cardiovascular death) with semaglutide versus placebo. Proposed mechanisms include reduced arterial inflammation, improved endothelial function (the lining of blood vessels), lower LDL and triglycerides, and slowed plaque progression. This was the first large trial to show a weight-loss drug reducing hard cardiovascular outcomes in non-diabetic patients.
Heart failure with preserved ejection fraction (HFpEF) Emerging human evidence — active trials
HFpEF is a form of heart failure where the heart pumps adequately but is too stiff to fill properly — obesity is a major driver. Early data suggest semaglutide reduces symptoms and improves exercise capacity in this population NCT05371496. Larger confirmatory trials are ongoing.
Neurodegenerative disease (Alzheimer's, Parkinson's) Early human trials — promising but not conclusive
GLP-1 receptors are expressed in brain regions affected by neurodegeneration, and several mechanisms — reduced neuroinflammation, improved insulin signaling in neurons — have been proposed. A review of early clinical trials found signals of benefit in both Alzheimer's and Parkinson's disease, but trials are small and results are preliminary Joanna 2025. This remains an active and genuinely interesting research area, not yet an established indication.
How it's used
In studies and approved clinical use, subcutaneous semaglutide starts at 0.25 mg once weekly for four weeks to minimize GI side effects, then increases every four weeks. Diabetes dosing typically lands at 0.5–2 mg weekly; the obesity dose (Wegovy) targets 2.4 mg weekly after a 16-week escalation. Injections go into the abdomen, thigh, or upper arm — same day each week, rotating sites. The oral form (Rybelsus) is taken fasted with no more than 4 oz of water, at least 30 minutes before the first food or drink of the day; food substantially reduces absorption. Compounded semaglutide formulations (widely used off-label) vary in concentration and purity — quality is not guaranteed outside regulated pharmacy supply chains Rodrigo 2025.
Side effects and safety
Nausea is the most common complaint, affecting 30–40% of users, and is most pronounced during dose escalation. Vomiting, diarrhea, constipation, and abdominal pain are reported at lower rates and typically improve within weeks Milena 2025. A case of transient intestinal ischemia (reduced blood flow to the gut) has been reported Reddy 2026 — rare, but worth knowing. Pancreatitis is a labeled risk; anyone with a prior episode should avoid this class. Thyroid C-cell tumors carry an FDA boxed warning based on rodent data — semaglutide is contraindicated with personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 syndrome. Acute kidney injury has been reported, likely secondary to dehydration from GI symptoms rather than direct renal toxicity. Slowed gastric emptying is relevant perioperatively — current guidance recommends holding GLP-1 agonists before procedures requiring general anesthesia Rodrigo 2025. Some data suggest a possible association with diabetic retinopathy progression at initiation (rapid glucose lowering may transiently worsen retinal disease); a separate signal around age-related macular degeneration is under investigation K 2025. Long-term effects beyond five years, including impacts on lean muscle mass during weight loss, remain incompletely characterized.
Bottom line
Semaglutide has more robust trial evidence behind it than almost any peptide or metabolic drug in current use — the weight loss and cardiovascular outcomes data are genuine and large-scale. It works best as part of a sustained lifestyle strategy; discontinuation leads to weight regain for most people. Anyone with a history of medullary thyroid cancer, MEN-2, pancreatitis, or gastroparesis should look elsewhere.